Hughes (antiphospholipid) syndrome clinical feature

Rheumatic Disease Clinics of North America

Volumn 27, Issue 3, 2001, Pages 507-524

  Cuadrado, Maria J ^b   Hughes, Graham R V ^b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOLIPID ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASE; CARDIOMYOPATHY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DIAGNOSTIC PROCEDURE; HUMAN; INTRACARDIAC THROMBOSIS; KIDNEY DISEASE; LUNG EMBOLISM; LUNG INFARCTION; MENTAL DISEASE; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SKIN MANIFESTATION; THROMBOCYTOPENIA; THROMBOSIS; VALVULAR HEART DISEASE;

EID: 0034858414     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(05)70217-9     Document Type: Article

References (151)

1. The presence of antiphospholipid antibodies in acute myocardial infarction
2. Increased endothelial cell expression of α3 β1-integrin in cardiac valvulopathy in the primary (Hughes) and secondary antiphospholipid syndrome
3. Resolution of vegetations with anticoagulation after myocardial infarction in primary antiphospholipid syndrome
4. Intracardiac thrombus in antiphospholipid antibody syndrome
5. Oral anticoagulation therapy of chronic skin ulcers in a patients with primary antiphospholipid syndrome
6. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients
7. Skin lesions associated with circulating lupus anticoagulant
8. Kidney disease in antiphospholipid syndrome
9. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke
10. Anticardiolipin antibodies and the risk of recurrent thrombo-occlusive events and death
11. Enrichment of antibodies against phospholipids in circulating immune complexes (CIC) in the antiphospholipid syndrome
12. Antiphospholipid antibodies and the lung
13. Antiphospholipid antibodies and chorea
14. Hypertension, renal artery stenosis and the "primary" antiphospholipid syndrome
15. Antiphospholipid antibodies: A risk factor for occlusive ocular vascular disease in systemic lupus erythematosus and the "primary" antiphospholipid syndrome
16. Postpartum bilateral renal vein thrombosis in the primary antiphospholipid syndrome
17. The "primary" antiphospholipid syndrome: Major clinical and serological features
18. The spectrum of livedo reticularis and anticardiolipin antibodies
19. Sneddon's syndrome and antiphospholipid antibodies
20. Prevalence and clinical significance of antiphospholipid antibodies in heart valve disease: A case control study
21. Cardiac involvement in patients with primary anti-phospholipid syndrome
22. Antiphospholipid antibodies and cerebral ischemia in young people
23. Beta-2-glycoprotein I-dependent anticardiolipin antibodies are an independent risk factor for ischemic stroke in the Honolulu heart cohort
24. Antiphospholipids in haemodialysis patients: Relationship between lupus anticoagulant and thrombosis
25. Anticardiolipin antibodies in acute non-hemorrhagic stroke seen within six hours after onset
26. Cerebral venous thrombosis and anticardiolipin antibodies
27. History of migraine and risk of cerebral ischemia in young adults
28. Ocular vaso-occlusive disease in primary antiphospholipid syndrome
29. Recent advances in antiphospholipid antibody-related valvulopathies
30. Chorea in antiphospholipid syndrome: Clinical, radiologic and immunologic characteristics of 50 patients from our clinics and recent literature
31. High prevalence of significant heart valve lesions in patients with the primary antiphospholipid syndrome
32. Anticardiolipin antibodies and physical disability in the elderly
33. Migraine and stroke in young women: Case-control study
34. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes
35. Antiphospholipid antibodies, prethrombotic states and stroke
36. Widespread cutaneous necrosis occurring in association with the antiphospholipid syndrome: A report of two cases
37. Migraine and stroke in young women
38. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature
39. Thrombocytopenia in the antiphospholipid syndrome
40. Widespread cutaneous necrosis and antiphospholipid antibodies: Two episodes related to surgical manipulation and urinary tract infection
41. Cognition and mood in systemic lupus erythematosus
42. The relationship of antiphospholipid antibodies to cognitive function in patients with systemic lupus erythematosus
43. Coagulation studies, factor V Leiden and anticardiolipin antibodies in 40 cases of cerebral venous sinus thrombosis
44. Antiphospholipid antibodies and retinal vascular disease
45. Increased IgM anticardiolipin antibodies in patients with restenosis after percutaneous transluminal coronary angioplasty
46. Clinical and immunological features of livedo reticularis in lupus: A case control study
47. Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary artery disease
48. Echocardiographic evaluation of patients with primary antiphospholipid syndrome
49. Antiphospholipid (aPL) antibodies in end-stage renal stage
50. Anticardiolipin antibodies, haemolytic anemia and thrombocytopenia in systemic lupus erythematosus
51. Antibodies to thromboplastin in systemic lupus erythematosus: Isotype distribution and clinical significance in a series of 92 patients
52. The mystery of Sneddon syndrome: Relationship with antiphospholipid syndrome and systemic lupus erythematosus
53. Multiple subungueal splinter hemorrhages in the antiphospholipid syndrome. A report of five cases and review of the literature
54. Sneddon syndrome with or without antiphospholipid antibodies: A comparative study in 46 patients
55. Alternating hemichorea in primary antiphospholipid syndrome: Evidence for contralateral striatal metabolism
56. Splenectomy for refractory thrombocytopenia in the antiphospholipid syndrome
57. Anti-glycoprotein Ib/IX and IIb/IIIa antibodies in patients with antiphospholipid antibodies
58. Valvular heart disease in the primary antiphospholipid syndrome
59. Anticardiolipin antibodies and lupus anticoagulant in endq stage renal disease
60. Valvular heart disease in primary antiphospholipid syndrome: Clinical and morphological findings
61. Anticardiolipin antibodies and occlusion of coronary bypass grafts
62. 2-glycoprotein I
63. Diffuse alveolar haemorrhage in the antiphospholipid syndrome: Spectrum of disease and treatment
64. Systemic therapy with fibrinolytic agents and heparin for recalcitrant nonhealing cutaneous ulcer in the antiphospholipid syndrome
65. Antiphospholipid syndrome and the skin
66. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis
67. Optic neuropathy in systemic lupus erythematosus and antiphospholipid syndrome (APS): Clinical features, pathogenesis, review of the literature and proposed ophthalmological criteria for APS diagnosis
68. Specific antiplatelet glycoprotein autoantibodies are associated with the thrombocytopenia of primary antiphospholipid syndrome
69. Antiphospholipid syndrome and renal artery stenosis
70. Antiphospholipid antibody syndrome: A new cause of non-healing skin ulcers
71. Vasculitis in the antiphospholipid syndrome: A cause of ischemia responding to corticosteroids
72. Unfading acral livedo
73. Autoimmune thrombocytopenia in primary antiphospholipid and systemic lupus erythematosus: The response to splenectomy
74. Antibodies to cardiolipin in young survivors of myocardial infarction: An association with recurrent cardiovascular events
75. A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus
76. Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus
77. Increased immunoglobulin binding to cerebral endothelium in patients with aPL
78. Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome
79. Connective tissue disease and the skin. The Prosser-White oration
80. Speculations on antiphospholipid syndrome in the coming millennium
81. Pulmonary veno-occlusive disease, antiphospholipid antibodies and pulmonary hypertension in an adolescent
82. Antiphospholipid antibodies in patients with multiple sclerosis and MS-like illnesses: MS or APS?
83. Risk factors for central nervous system involvement in systemic lupus erythematosus
84. Sneddon's syndrome: Cardiac pathology and antiphospholipid antibodies
85. Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus
86. Immune mediated mechanism for thrombosis: Antiphospholipid antibody binding to platelet membranous
87. Vaso-occlusive retinopathy associated with antiphospholipid antibodies (lupus anticoagulant retinopathy)
88. Pulmonary hypertension and the antiphospholipid syndrome
89. Autoimmune haemolytic anemia in patients with systemic lupus erythematosus
90. A retrospective review of 61 patients with antiphospholipid syndrome
91. Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 Cases
92. Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome
93. Allograft membranous glomerulonephritis and renal vein thrombosis in a patient with a lupus anticoagulant factor
94. Anticardiolipin antisera from lupus patients with seizures reduce a GABA receptor-mediated chloride current in snail neurons
95. Serum lymphocytotoxic antibodies and neurocognitive function in systemic lupus erythematosus
96. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study
97. Anticardiolipin antibodies, livedo reticularis and major cerebrovascular and renal disease in systemic lupus erythematosus
98. A longitudinal study of anticardiolipin antibody levels and functioning in systemic lupus erythematosus
99. Association between migraine and stroke in a large-scale epidemiological study of the United States
100. The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases
101. Heart valve disease in systemic lupus erythematosus. Role of antiphospholipid antibodies
102. Neurocognitive deficits in antiphospholipid syndrome
103. Recurrent renal thrombotic angiopathy after kidney transplantation in two patients with primary antiphospholipid syndrome (PAPS)
104. Antiphospholipid antibodies in cerebral ischemia
105. Lack of association between anticardiolipin antibodies and migraine in systemic lupus erythematosus
106. Value of immunologic testing in stroke patients: A prospective multicentric study
107. Renal vein thrombosis caused by primary antiphospholipid syndrome
108. Coronary artery bypass graft failure: An autoimmune phenomenon?
109. Prevalence and clinical significance of subungueal splinter haemorrhage in patients with the antiphospholipid syndrome
110. Sudden sensorineural hearing loss in patients with systemic lupus erythematosus or lupus-like syndromes and antiphospholipid antibodies
111. Cutaneous manifestations associated with antiphospholipid antibodies in patients with suspected primary APS: A case control study
112. Systemic lupus erythematosus with myocardial dysfunction microvasculopathy
113. Valvular dysfunction in antiphospholipid syndrome: Prevalence, clinical features and treatment
114. The intrarenal vascular lesions associated with primary antiphospholipid syndrome
115. Extensive cutaneous necrosis associated with anticardiolipin antibodies
116. Specificities of platelet autoantibodies in patients with lupus anticoagulants in primary antiphospholipid syndrome
117. Pulmonary hypertension and antiphospholipid antibodies
118. Antibodies to oxidized low-density lipoprotein predicting myocardial infarction
119. Renal transplantation in anticardiolipin antibody-positive lupus erythematosus patients
120. A reversible bilateral renal artery stenosis in association with antiphospholipid syndrome
121. Painful nodules in a young female
122. The concomitant of vasculitis and vasculopathy: Synergy for marked tissue ischemia
123. Systemic lupus erythematosus valve disease by transesophageal echocardiography and the role of antiphospholipid antibodies
124. Anticardiolipin antibodies and renovascular hypertension
125. Autoantibodies to phospholipid-binding plasma proteins: A new view of lupus anticoagulants and the antiphospholipid antibodies
126. Cerebrovascular lesions and livedo reticularis (Sneddon's syndrome) - A progressive cerebrovascular disorder
127. Prevalence of headache and relationship with the presence of antiphospholipid antibodies in systemic lupus erythematosus
128. Outcome of patients with anticardiolipin antibodies: A 10 year follow-up of 52 patients
129. Cerebrovascular lesions and livedo reticularis
130. Lupus anticoagulant and the skin. A long term follow-up study of SLE patients with special reference to histopathological findings
131. The role of anticardiolipin autoantibodies in the pathogenesis of autoimmune hemolytic anaemia in systemic lupus erythematosus
132. Outcome of renal transplantation in SLE: 97 Cyclosporine-era patients and matched controls
133. Cardiovascular disease in systemic lupus erythematosus: A study of 75 patients from a defined population
134. Reversible chorea in primary antiphospholipid syndrome
135. Role of anticardiolipin antibodies in young persons with migraine and transient focal neurologic events
136. Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus
137. Autoimmune aberration in sudden sensorineural hearing loss: Association with anticardiolipin antibodies
138. The natural course of cerebral lesions in Sneddon syndrome
139. Case-control study of migraine and risk of ischemic stroke in young women
140. Affinity-purified cardiolipin-binding antibodies show heterogeneity in their binding to oxidized low-density lipoprotein
141. Anticardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men
142. Frequency, potential risk and therapeutic intervention in end-stage renal disease patients with antiphospholipid antibody syndrome: A multicenter study
143. Relative risk of post-transplant renal thrombosis in patients with antiphospholipid antibodies
144. Reversible dementia and chorea in a young woman with the lupus anticoagulant
145. Prevalence and significance of antinuclear and anticardiolipin antibodies in patients with epilepsy
146. Comparison of the primary and secondary antiphospholipid syndrome: A European multicenter study of 114 patients
147. Livedo reticularis associated with increased titres of anticardiolipin antibodies in systemic lupus erythematosus
148. Primary antiphospholipid antibody syndrome and retinal occlusive vasculopathy
149. The oxidation hypothesis of atherosclerosis
150. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction
151. Anticardiolipin antibodies and acute myocardial infarction in non-systemic lupus erythematosus: A controlled prospective study